Percutaneous absorption of interferon-alpha by self-dissolving micropiles
Yukako Ito1, Atsushi Saeki, Keiji Shiroyama
1Department of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan. yukako@mb.kyoto-phu.ac.jp
Chondroitin sulfate-based self-dissolving micropiles (SDMPs) significantly enhance interferon (IFN) bioavailability compared to dextran-based SDMPs and subcutaneous injection. These IFN-loaded chondroitin sulfate SDMPs demonstrate excellent stability and skin compatibility.
Area of Science:
- Biomedical Engineering
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Interferon (IFN) is a crucial therapeutic protein with limited oral bioavailability.
- Developing effective delivery systems for IFN is essential for improving therapeutic outcomes.
- Self-dissolving micropiles (SDMPs) offer a promising approach for transdermal drug delivery.
Purpose of the Study:
- To evaluate the pharmaceutical utility of self-dissolving micropiles (SDMPs) loaded with interferon (IFN).
- To compare the efficacy of chondroitin sulfate-based and dextran-based SDMPs for IFN delivery.
- To assess the in vivo pharmacokinetic profile and bioavailability of IFN delivered via SDMPs.
Main Methods:
- Two types of IFN-loaded SDMPs were fabricated using chondroitin sulfate and dextran.
- Percutaneous administration of IFN-alpha2b SDMPs (5000 IU/kg) to rats.
- Serum IFN levels were monitored for 6 hours to determine pharmacokinetic parameters (Cmax, Tmax, AUC).
- In vitro drug release studies and assessment of SDMP stability and skin compatibility were performed.
Main Results:
- Chondroitin sulfate SDMPs achieved a higher Cmax (8.2 IU/ml) and faster Tmax (1.2 h) compared to dextran SDMPs (Cmax: 3.1 IU/ml, Tmax: 3.3 h).
- The bioavailability of IFN from chondroitin sulfate SDMPs was significantly higher (378.3%) than from dextran SDMPs (255.9%) and subcutaneous injection (320.9%).
- Chondroitin sulfate SDMPs exhibited a faster in vitro IFN release rate and demonstrated good stability and no skin irritation over 3 months.
Conclusions:
- Chondroitin sulfate-based SDMPs are a superior delivery system for interferon, enhancing its bioavailability and pharmacokinetic profile.
- These SDMPs offer a stable and safe alternative to conventional subcutaneous injection for IFN administration.
- The findings support the pharmaceutical potential of chondroitin sulfate SDMPs for transdermal delivery of therapeutic proteins like interferon.
More Related Videos
09:42Development of an Economical DNA Delivery System by "Acufection" and its Application to Skin Research
Published on: April 19, 2017
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Non-Oral Extravascular Drug Absorption Routes
Lipophilic drugs that are stable at salivary pH (6) and exhibit minimal binding to the oral mucosa are absorbed more effectively...
